Still don't have an immediate statin protocol therapy for better recovery? Why hasn't everyone here been fired yet?
Your competent? doctor immediately prescribed statins post stroke based on earlier research, right? NO? And still hasn't been fired yet?
1. Statins.
tested in rats from 2003
http://Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke
Simvastatin Attenuates Stroke-induced Splenic Atrophy and Lung Susceptibility to Spontaneous Bacterial Infection in Mice
Or,
Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons
October 2012
tested in humans, March 2011
http://www.medwirenews.com/39/91658/Stroke/Acute_statin_therapy_improves_survival_after_ischemic_stroke.html
And now lost even to the Wayback Machine
So, I think this below is the actual research.
Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke April 2011
The latest here:
Intensive versus standard statin therapy in acute ischemic stroke: a comparative study on the risk of pneumonia and multidrug-resistant bacterial infections
Abstract
Background:
The use of intensive statin therapy in acute ischemic stroke (AIS) is common; however, its association with post-stroke pneumonia (PSP) remains uncertain. This study aimed to determine whether intensive-dose atorvastatin (≥40 mg/d) increases the risk, severity, or incidence of multidrug-resistant (MDR) bacterial infections in PSP compared to standard-dose therapy (20 mg/d).
Methods:
We retrospectively analyzed 4,843 AIS patients admitted to the First Affiliated Hospital of Wenzhou Medical University between January 2020 and January 2022. After applying inclusion and exclusion criteria, 3,199 patients were included. Propensity score matching (PSM) was used to balance baseline characteristics between the intensive and standard atorvastatin groups. The incidence of PSP, pneumonia severity (evaluated by CURB-65 scores), and MDR bacterial infection rates were compared. Multivariate logistic regression was applied to identify independent risk factors for PSP.
Results:
After PSM, no significant difference was observed in PSP incidence between the intensive and standard atorvastatin groups (8.8% vs. 8.3%, p = 0.691). Multivariate regression confirmed that intensive treatment was not associated with increased PSP risk, either before (OR = 1.074, 95% CI: 0.756–1.525) or after matching (OR = 1.002, 95% CI: 0.672–1.492). Among the 173 PSP patients, there were no significant differences in the proportion of severe pneumonia (21.4% vs. 20.2%, p = 0.863) or MDR bacterial infection incidence (9.5% vs. 10.1%, p = 0.897) between the two groups.
Conclusion:
High-intensity atorvastatin therapy during the acute phase of ischemic stroke did not increase the risk or severity of pneumonia, nor did it elevate MDR bacterial infections. These findings suggest that intensive atorvastatin therapy is not associated with an increased risk of PSP and offer insights for optimizing clinical treatment strategies.
No comments:
Post a Comment